181 related articles for article (PubMed ID: 34066763)
1. Insights into the Behavior of Triple-Negative MDA-MB-231 Breast Carcinoma Cells Following the Treatment with 17β-Ethinylestradiol and Levonorgestrel.
Simu S; Marcovici I; Dobrescu A; Malita D; Dehelean CA; Coricovac D; Olaru F; Draghici GA; Navolan D
Molecules; 2021 May; 26(9):. PubMed ID: 34066763
[TBL] [Abstract][Full Text] [Related]
2. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
3. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
[TBL] [Abstract][Full Text] [Related]
4. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.
Klipping C; Duijkers I; Parke S; Mellinger U; Serrani M; Junge W
Drugs R D; 2011; 11(2):159-70. PubMed ID: 21679006
[TBL] [Abstract][Full Text] [Related]
5. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
6. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU
Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698
[TBL] [Abstract][Full Text] [Related]
7. Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives.
Nielsen CH; Poulsen HK; Teisner B; Thorsen P; Hau J; Westergaard JG
Eur J Obstet Gynecol Reprod Biol; 1993 Sep; 51(1):63-71. PubMed ID: 7506680
[TBL] [Abstract][Full Text] [Related]
8. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
9. Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles.
Skouby SO; Mølsted-Pedersen L; Kühl C; Bennet P
Fertil Steril; 1986 Nov; 46(5):858-64. PubMed ID: 3781003
[TBL] [Abstract][Full Text] [Related]
10. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
11. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
12. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
13. Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function.
Seeger H; Petersen G; Schulte-Wintrop E; Teichmann AT; Mueck AO
Int J Clin Pharmacol Ther; 2002 Apr; 40(4):150-7. PubMed ID: 11996209
[TBL] [Abstract][Full Text] [Related]
14. Metabolic changes during treatment with two different progestogens.
Refn H; Kjaer A; Lebech AM; Borggaard B; Schierup L; Bremmelgaard A
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):374-7. PubMed ID: 2115298
[TBL] [Abstract][Full Text] [Related]
15. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative and antimetastatic properties of 3-benzyloxy-16-hydroxymethylene-estradiol analogs against breast cancer cell lines.
Sinka I; Kiss A; Mernyák E; Wölfling J; Schneider G; Ocsovszki I; Kuo CY; Wang HC; Zupkó I
Eur J Pharm Sci; 2018 Oct; 123():362-370. PubMed ID: 30010030
[TBL] [Abstract][Full Text] [Related]
17. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
Ünal TD; Hamurcu Z; Delibaşı N; Çınar V; Güler A; Gökçe S; Nurdinov N; Ozpolat B
Anticancer Agents Med Chem; 2021; 21(3):355-364. PubMed ID: 32767958
[TBL] [Abstract][Full Text] [Related]
18. Triterpenoid Saponin AG8 from
Mu LH; Wang LH; Yu TF; Wang YN; Yan H; Liu P; Yan C
Oxid Med Cell Longev; 2020; 2020():7963212. PubMed ID: 33123316
[TBL] [Abstract][Full Text] [Related]
19. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
20. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function.
Ågren UM; Anttila M; Mäenpää-Liukko K; Rantala ML; Rautiainen H; Sommer WF; Mommers E
Eur J Contracept Reprod Health Care; 2011 Dec; 16(6):458-67. PubMed ID: 21942708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
